Medicare’s weight-loss drug discount excludes many who need it most, new cases reveal

Despite a new Medicare pilot programme aimed at making GLP-1 weight-loss medications more affordable, restrictions based on health conditions leave out many patients, including a retired professor with severe obesity and health issues.

Jeff La Marca thought he had found a way to make a high-priced weight-loss drug affordable when Medicare unveiled its new GLP-1 pilot programme. But the 68-year-old retired professor from Basking Ridge, New Jersey, soon learned that the much-publicised discount does not apply to everyone who might benefit from the medicines.

La Marca was prescribed Zepbound in January, but the roughly $750 monthly price put it out of reach. When the Medicare initiative launched on 1 July 2026, he applied in the hope that the plan’s $50 copayment would finally bring treatment within reach. Instead, his request was rejected because he has severe obstructive sleep apnoea, one of the conditions that rules patients out of the discount programme. He said he has obesity, a body mass index of 42, a history of quadruple bypass surgery and prediabetes, and he described the denial as infuriating.

The Medicare demonstration, known as the GLP-1 Bridge programme, covers Wegovy, Zepbound’s KwikPen version and Foundayo for eligible Part D enrollees. According to Medicare guidance, people qualify if they are 18 or older and have a BMI of at least 35, or a BMI of at least 30 with certain health conditions. But the official rules also say people with type 2 diabetes, moderate to severe sleep apnoea or fatty liver disease are not eligible for the $50 option. For those patients, the drugs are pushed back into ordinary Part D coverage, where monthly out-of-pocket costs can still run into the hundreds of dollars.

That gap is precisely what frustrates doctors and patient advocates. Taylor Lacy, a primary care physician in Roeland Park, Kansas, told KFF Health News that coverage does not always mean affordability. She said many older patients are already facing prior authorisation hurdles and step therapy, the process that requires them to try cheaper drugs first, before discovering that their GLP-1 copayments remain too high. Medicare says the early weeks of the pilot have been smooth, with most prior authorisation requests completed in less than 12 hours, but the federal government has not released a cost estimate for the programme. Juliette Cubanski, who leads Medicare policy research at KFF, has estimated that the programme could cost Medicare billions depending on uptake.

For La Marca, the result is a familiar dead end: a medicine his doctors want him to take, a benefit that exists on paper and a price he still cannot afford. He said he has tried diets and exercise regimes without success and now sees the drug as his last real chance to improve his health. His insurer declined to address his case specifically, while industry group AHIP blamed drugmakers for setting prices it says they could lower.